Login to Your Account

Other news to note

Monday, December 16, 2013
Bind Therapeutics Inc., of Cambridge, Mass., and Amgen Inc., of Thousand Oaks, Calif., amended their development and commercialization collaboration agreement to extend the period during which Amgen may exercise its option by six months.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription